MedTrace Logo

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

NCT07185321 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-09-22

No results posted yet for this study

Summary

This is a single-center, Phase 1, open-label, 3-period, fixed-sequence study to investigate the bioavailability, absorption, metabolism, excretion and the safety of mosliciguat administered to healthy male adults.

Conditions

  • Healthy Volunteer

Interventions

DRUG

Mosliciguat

Dose level for inhalation

DRUG

14C mosliciguat

Dose level

DEVICE

Dry Powder Inhaler

Dry powder inhaler for mosliciguat

Sponsors & Collaborators

  • Pulmovant, Inc.

    lead INDUSTRY

Principal Investigators

  • Ubaldo Martin · Pulmovant, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-10
Primary Completion
2026-03-31
Completion
2026-05-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185321 on ClinicalTrials.gov